Sphingolipids : From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid

Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the bod...

Полное описание

Сохранить в:
Библиографические подробности
Другие авторы: van Echten-Deckert, Gerhild (Редактор)
Формат: Глава книги
Опубликовано: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Предметы:
Online-ссылка:Get Fullteks
DOAB: description of the publication
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!
LEADER 05327naaaa2201321uu 4500
001 doab_20_500_12854_76606
005 20220111
020 |a books978-3-03943-958-4 
020 |a 9783039439577 
020 |a 9783039439584 
024 7 |a 10.3390/books978-3-03943-958-4  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a GP  |2 bicssc 
072 7 |a PS  |2 bicssc 
100 1 |a van Echten-Deckert, Gerhild  |4 edt 
700 1 |a van Echten-Deckert, Gerhild  |4 oth 
245 1 0 |a Sphingolipids : From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (292 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the body-and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
653 |a S1P receptor 
653 |a inflammation 
653 |a S1P transporter 
653 |a spinster homolog 2 
653 |a barrier dysfunction 
653 |a anxiety 
653 |a depression 
653 |a sphingolipids 
653 |a sphingomyelinase 
653 |a ceramidase 
653 |a Smpd1 
653 |a acid sphingomyelinase 
653 |a forebrain 
653 |a depressive-like behavior 
653 |a anxiety-like behavior 
653 |a ceramide 
653 |a ceramides 
653 |a ceramidases 
653 |a neurodegenerative diseases 
653 |a infectious diseases 
653 |a sphingosine 1-phoshate 
653 |a sphingosine 1-phosphate receptor 
653 |a S1P1-5 
653 |a sphingosine 1-phosphate metabolism 
653 |a sphingosine 1-phosphate antagonistst/inhibitors 
653 |a sphingosine 1-phosphate signaling 
653 |a stroke 
653 |a multiple sclerosis 
653 |a neurodegeneration 
653 |a fingolimod 
653 |a Sphingosine-1-phosphate 
653 |a obesity 
653 |a type 2 diabetes 
653 |a insulin resistance 
653 |a pancreatic β cell fate 
653 |a hypothalamus 
653 |a sphingosine-1-phosphate 
653 |a ischemia/reperfusion 
653 |a cardioprotection 
653 |a vasoconstriction 
653 |a coronary flow 
653 |a myocardial function 
653 |a myocardial infarct 
653 |a albumin 
653 |a type 1 diabetes 
653 |a beta-cells 
653 |a islets 
653 |a insulin 
653 |a cytokines 
653 |a S1P 
653 |a animal models 
653 |a cystic fibrosis 
653 |a autophagy 
653 |a myriocin 
653 |a Aspergillus fumigatus 
653 |a CLN3 disease 
653 |a Cln3Δex7/8 mice 
653 |a flupirtine 
653 |a allyl carbamate derivative 
653 |a apoptosis 
653 |a cancer 
653 |a gangliosides 
653 |a immunotherapy 
653 |a metastasis 
653 |a phenotype switching 
653 |a sphingosine 1-phosphate 
653 |a Sphingosine 1-phosphate (S1P) 
653 |a S1P-lyase (SGPL1) 
653 |a tau 
653 |a calcium 
653 |a histone acetylation 
653 |a hippocampus 
653 |a cortex 
653 |a astrocytes 
653 |a neurons 
653 |a sphingosine kinase 
653 |a G-protein-coupled receptors 
653 |a Gαq/11 
653 |a n/a 
653 |a sphingosine kinase 1 
653 |a SK1 
653 |a microRNA 
653 |a transcription factor 
653 |a hypoxia 
653 |a long non-coding RNA 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/4051  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/76606  |7 0  |z DOAB: description of the publication